GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » Shiller PE Ratio

XBiotech (XBiotech) Shiller PE Ratio : 8.77 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is XBiotech Shiller PE Ratio?

As of today (2024-05-15), XBiotech's current share price is $8.59. XBiotech's E10 for the quarter that ended in Mar. 2024 was $0.98. XBiotech's Shiller PE Ratio for today is 8.77.

The historical rank and industry rank for XBiotech's Shiller PE Ratio or its related term are showing as below:

XBIT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.07   Med: 4.75   Max: 9.25
Current: 8.77

During the past years, XBiotech's highest Shiller PE Ratio was 9.25. The lowest was 3.07. And the median was 4.75.

XBIT's Shiller PE Ratio is ranked better than
92.72% of 151 companies
in the Biotechnology industry
Industry Median: 35.74 vs XBIT: 8.77

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

XBiotech's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.330. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.98 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


XBiotech Shiller PE Ratio Historical Data

The historical data trend for XBiotech's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech Shiller PE Ratio Chart

XBiotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 4.03

XBiotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.16 5.69 4.12 4.03 8.32

Competitive Comparison of XBiotech's Shiller PE Ratio

For the Biotechnology subindustry, XBiotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XBiotech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XBiotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where XBiotech's Shiller PE Ratio falls into.



XBiotech Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

XBiotech's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=8.59/0.98
=8.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XBiotech's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, XBiotech's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.33/129.4194*129.4194
=-0.330

Current CPI (Mar. 2024) = 129.4194.

XBiotech Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.123 100.560 -0.158
201409 -0.220 100.428 -0.284
201412 -0.200 99.070 -0.261
201503 -0.256 99.621 -0.333
201506 -0.220 100.684 -0.283
201509 -0.330 100.392 -0.425
201512 -0.380 99.792 -0.493
201603 -0.320 100.470 -0.412
201606 -0.420 101.688 -0.535
201609 -0.380 101.861 -0.483
201612 -0.510 101.863 -0.648
201703 -0.320 102.862 -0.403
201706 -0.260 103.349 -0.326
201709 -0.180 104.136 -0.224
201712 -0.230 104.011 -0.286
201803 -0.110 105.290 -0.135
201806 -0.160 106.317 -0.195
201809 -0.140 106.507 -0.170
201812 -0.170 105.998 -0.208
201903 -0.160 107.251 -0.193
201906 -0.160 108.070 -0.192
201909 -0.150 108.329 -0.179
201912 16.534 108.420 19.736
202003 0.000 108.902 0.000
202006 -0.240 108.767 -0.286
202009 -0.090 109.815 -0.106
202012 -0.060 109.897 -0.071
202103 -0.090 111.754 -0.104
202106 -0.170 114.631 -0.192
202109 -0.110 115.734 -0.123
202112 -0.210 117.630 -0.231
202203 -0.180 121.301 -0.192
202206 -0.380 125.017 -0.393
202209 -0.420 125.227 -0.434
202212 -0.100 125.222 -0.103
202303 -0.130 127.348 -0.132
202306 -0.290 128.729 -0.292
202309 -0.240 129.860 -0.239
202312 -0.160 129.419 -0.160
202403 -0.330 129.419 -0.330

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XBiotech  (NAS:XBIT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


XBiotech Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of XBiotech's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XBiotech (XBiotech) Business Description

Traded in Other Exchanges
Address
5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Executives
Angela Hu officer: Principle Financial Officer 5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard director, 10 percent owner 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a. 10 percent owner MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie director, 10 percent owner 735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy officer: VP of R&D 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han officer: VP of Fin & HR, Secretary 8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut 10 percent owner CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby director 109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes 10 percent owner RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam director 56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin director 77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman officer: Sr.VP Corp. Strategy & Finance 8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson officer: VP of Commercial Development 8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury officer: VP of Business Development 8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough officer: VP Clinical Operations 115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703

XBiotech (XBiotech) Headlines

From GuruFocus

FDA Approves XBiotech's IND in Rheumatology

By GuruFocusNews GuruFocusNews 12-13-2021

Xbiotech Inc (XBIT) CEO John Simard Sold $757,500 of Shares

By GuruFocus Research GuruFocus Editor 09-23-2021